Ascendis Pharma A/S

XNAS

Last traded price · USD

$257.21

−0.28%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:05 IST · A quote does not mean the product is available to trade on your account.

Day's open: $257.93
Previous close: $257.93
Volume: 6,166
Day's high: $257.93
Day's low: $254.33

In brief

Ascendis Pharma A/S is a US-listed company listed on Nasdaq, valued at about $16.93B.
Its shares closed at $257.93 on 4 Nov 2026, up 23.9% over the past year.
From India you can buy ASND in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Ascendis Pharma A/S (ASND) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole ASND share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade ASND options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY over 1 year
1 month: +14.1% (SPY −1.6%). 3 months: +5.6% (SPY −0.4%). 1 year: +23.9% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ASND, SPY · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $257.93 was 6.5% above its 50-day average ($242.28) and 8.1% above its 200-day average ($238.70). It has closed above the 200-day for 11 sessions, since 21 Oct 2026. The 50-day average crossed above the 200-day on 18 Feb 2025, 431 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
74% of the way up its 52-week range
Closed at $257.93 on 4 Nov 2026: 8.6% below the 52-week high of $282.15 (9 Jul 2026) and 37.1% above the low of $188.07 (13 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
3.1M shares sold short
3.1M shares were sold short at the 15 Oct 2026 settlement; covering them would take 4.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+14.1%

6 months+9.3%

1 year+23.9%

5 years+61.1%

Newswire

About

Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.

Website

Notable moves

September 16, 2024
+17.07%
May 1, 2023
+23.99%
April 3, 2023
−32.07%

Ascendis Pharma A/S

XNAS

Last traded price · USD

$257.21

−0.28%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:05 IST · A quote does not mean the product is available to trade on your account.

Day's open: $257.93
Previous close: $257.93
Volume: 6,166
Day's high: $257.93
Day's low: $254.33

In brief

Ascendis Pharma A/S is a US-listed company listed on Nasdaq, valued at about $16.93B.
Its shares closed at $257.93 on 4 Nov 2026, up 23.9% over the past year.
From India you can buy ASND in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Ascendis Pharma A/S (ASND) shares from India?

Do I need the price of a whole ASND share to invest?

How much can I invest in US stocks in a year?

Can I trade ASND options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY over 1 year
1 month: +14.1% (SPY −1.6%). 3 months: +5.6% (SPY −0.4%). 1 year: +23.9% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ASND, SPY · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $257.93 was 6.5% above its 50-day average ($242.28) and 8.1% above its 200-day average ($238.70). It has closed above the 200-day for 11 sessions, since 21 Oct 2026. The 50-day average crossed above the 200-day on 18 Feb 2025, 431 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
74% of the way up its 52-week range
Closed at $257.93 on 4 Nov 2026: 8.6% below the 52-week high of $282.15 (9 Jul 2026) and 37.1% above the low of $188.07 (13 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
3.1M shares sold short
3.1M shares were sold short at the 15 Oct 2026 settlement; covering them would take 4.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+14.1%

6 months+9.3%

1 year+23.9%

5 years+61.1%

Newswire

About

Website

Notable moves

September 16, 2024
+17.07%
May 1, 2023
+23.99%
April 3, 2023
−32.07%

Ascendis Pharma A/S

Ascendis Pharma A/S in brief

Ahead of SPY over 1 year

Above its 50- and 200-day averages

74% of the way up its 52-week range

3.1M shares sold short

Ascendis Pharma A/S

Ascendis Pharma A/S in brief

Ahead of SPY over 1 year

Above its 50- and 200-day averages

74% of the way up its 52-week range

3.1M shares sold short